<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03250169</url>
  </required_header>
  <id_info>
    <org_study_id>011717</org_study_id>
    <nct_id>NCT03250169</nct_id>
  </id_info>
  <brief_title>Neurofilaments for NEDA Assessing in MS</brief_title>
  <official_title>Neurofilament Heavy and Light Chain Testing for NEDA (No Evidence of Disease Activity) Assessing in Multiple Sclerosis: a Longitudinal Biomarker Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Mary University of London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Queen Mary University of London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Goal is to evaluate the achievement of biological NEDA as demonstrated by a drop in
      neurofilament levels in MS patients commencing Alemtuzumab therapy as part of their MS
      management.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary

        1. To evaluate the achievement of NEDA using blood and CSF neurofilaments in Alemtuzumab
           treated patients.

           Secondary

        2. To assess prognosis at the end of the study based on neurofilament status.

        3. To correlate neurofilament levels with clinical and MRI markers of disease activity.

        4. To evaluate the effect of Alemtuzumab on the profile of other CSF, blood, urine, faeces
           biomarkers of inflammation, neurodegeneration, neuronal sprouting and synaptogenesis,
           treatment activity and metabolic activity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Blood and CSF neurofilaments in Alemtuzumab patients over 24months</measure>
    <time_frame>2 years</time_frame>
    <description>Neurofilaments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall clinical response based on neurofilament response</measure>
    <time_frame>2 years</time_frame>
    <description>neurofilaments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurofilament status and association with clinical and MRI markers of disease activity.</measure>
    <time_frame>2 years</time_frame>
    <description>Correlation index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal assessment of other biomarkers of inflammation &amp; plasticity</measure>
    <time_frame>2 years</time_frame>
    <description>Correlation index</description>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Multiple Sclerosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alemtuzumab</intervention_name>
    <description>Licensed dose</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Relapsing-remitting MS
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS).

          2. Age 18-55 years.

          3. EDSS score between 0-5.5.

          4. Commencing Alemtuzumab therapy at Neurology Infusion and Planned Investigation Unit,
             The Royal London Hospital, Ward 11D

        Exclusion Criteria:

          1. A diagnosis of Secondary Progressive MS (SPMS) or other forms of progressive MS.

          2. Those unable to comply with study requirement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Francesca Ammoscato</last_name>
    <phone>02078822282</phone>
    <email>f.ammoscato@qmul.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Queen Mary University of London</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>E1 2AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Ammoscato</last_name>
      <email>f.ammoscato@qmul.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2017</study_first_submitted>
  <study_first_submitted_qc>August 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2017</study_first_posted>
  <last_update_submitted>August 10, 2017</last_update_submitted>
  <last_update_submitted_qc>August 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

